As a matter of fact, we expanded our previous results showing that PSEN1, involved in amyloidogenic processing, is modulated by the methylation status of its promoter region and that SAM supplementation can represent a possible intervention to modulate its expression without completely inhibiting its enzymatic activity, and thus mitigating senile plaque deposition and AD progression. Here, PSEN1 is linked to Alzheimer disease.